amantadine has been researched along with propranolol in 43 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 16 (37.21) | 18.7374 |
1990's | 2 (4.65) | 18.2507 |
2000's | 13 (30.23) | 29.6817 |
2010's | 11 (25.58) | 24.3611 |
2020's | 1 (2.33) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Agnoli, A; Carolei, A; Casacchia, M; Fazio, C; Zamponi, A | 1 |
Stone, TW | 1 |
Eisdorfer, C | 1 |
McKinney, AS | 1 |
Bergen, D; Goetz, C; Klawans, HL | 1 |
Salvador, AM | 1 |
Camanni, F; Isaia, GC; Massara, F; Molinatti, GM | 1 |
Culvenor, AJ; Dawson, RM; Freeman, SE; Keeghan, AM | 1 |
Casey, DE; Keepers, GA | 1 |
Young, RR | 1 |
Jan, JE; Wilson, RA | 1 |
Schwab, RS; Young, RR | 1 |
Kubo, T; Takagi, H | 1 |
Bauman, AW; Hammond, EJ; Karas, BJ; Wilder, BJ | 1 |
Goetz, CG; Klawans, HL; Tanner, CM | 1 |
Hostetler, KY; Matsuzawa, Y | 1 |
Ahlskog, JE | 1 |
Guin-Renfroe, S; Meythaler, JM; Wilkinson, R | 1 |
Koller, W; Marjama-Lyons, J | 1 |
Fleminger, S; Greenwood, RJ; Oliver, DL | 2 |
Schmidt, JG; Schneider, WN | 1 |
Atzram, M; Dackis, C; Gariti, P; Kampman, KM; Lynch, KG; O'Brien, CP; Pettinati, H; Sparkman, T; Tirado, C | 1 |
Aschermann, Z; Horváth, K; Komoly, S; Kovács, A; Kovács, N | 1 |
Lerner, PP; Lerner, V; Miodownik, C | 1 |
8 review(s) available for amantadine and propranolol
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical management of acute neuroleptic-induced extrapyramidal syndromes.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Child; Disease Susceptibility; Double-Blind Method; Dystonia; Female; Humans; Male; Middle Aged; Parasympatholytics; Parkinson Disease, Secondary; Propranolol; Psychomotor Agitation; Risk | 1986 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
Tremor-predominant Parkinson's disease. Approaches to treatment.
Topics: Acetates; Amantadine; Amines; Antiparkinson Agents; Botulinum Toxins; Cholinergic Antagonists; Clonazepam; Clozapine; Cyclohexanecarboxylic Acids; Dopamine Agonists; Electric Stimulation Therapy; Gabapentin; Gamma Rays; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Neurosurgical Procedures; Parkinson Disease; Propranolol; Radiosurgery; Thalamus; Tremor | 2000 |
Pharmacological management for agitation and aggression in people with acquired brain injury.
Topics: Adrenergic beta-Antagonists; Aggression; Amantadine; Anxiety; Brain Injuries; Humans; Methylphenidate; Neuroprotective Agents; Pindolol; Propranolol; Randomized Controlled Trials as Topic | 2003 |
Pharmacological management for agitation and aggression in people with acquired brain injury.
Topics: Adrenergic beta-Antagonists; Aggression; Amantadine; Anxiety; Brain Injuries; Humans; Methylphenidate; Neuroprotective Agents; Pindolol; Propranolol; Psychomotor Agitation; Randomized Controlled Trials as Topic | 2006 |
[Treatment of tardive syndromes].
Topics: Amantadine; Antipsychotic Agents; Botulinum Toxins; Central Nervous System Agents; Cholinergic Antagonists; Clinical Trials as Topic; Clonazepam; Deep Brain Stimulation; Dopamine Antagonists; Ginkgo biloba; Humans; Levetiracetam; Movement Disorders; Nootropic Agents; Piracetam; Primary Prevention; Propranolol; Syndrome; Tetrabenazine; Vitamin E | 2014 |
Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; alpha-Tocopherol; Amantadine; Anticonvulsants; Antioxidants; Antipsychotic Agents; Clonazepam; Dopamine Agents; Drugs, Chinese Herbal; Fatty Acids, Omega-3; Ginkgo biloba; Humans; Isoleucine; Isoxazoles; Leucine; Levetiracetam; Melatonin; Movement Disorders; Nootropic Agents; Piracetam; Plant Extracts; Propranolol; Pyridoxine; Resveratrol; Stilbenes; Tetrabenazine; Valine; Vitamins; Zonisamide | 2015 |
2 trial(s) available for amantadine and propranolol
Article | Year |
---|---|
Treatment of valproate tremors.
Topics: Amantadine; Cyproheptadine; Diphenhydramine; Humans; Propranolol; Tremor; Valproic Acid | 1983 |
A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms.
Topics: Adrenergic beta-Antagonists; Adult; Amantadine; Analgesics, Non-Narcotic; Cocaine; Cocaine-Related Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Neurologic Examination; Patient Dropouts; Propranolol; Substance Abuse Detection; Substance Withdrawal Syndrome | 2006 |
33 other study(ies) available for amantadine and propranolol
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[Therapy of Parkinson's disease. Practical criteria of treatment].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Carbidopa; Cyproheptadine; Drug Therapy, Combination; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Piribedil; Pizotyline; Propranolol | 1976 |
Comparison of neuronal responses to amantadine and rimantadine: use of alpha-flupenthixol.
Topics: Adamantane; Amantadine; Animals; Bridged-Ring Compounds; Cerebral Cortex; Dopamine Antagonists; Flupenthixol; Male; Neurons; Phentolamine; Propranolol; Rats; Synaptic Transmission; Thioxanthenes | 1978 |
Observations on the psychopharmacology of the aged.
Topics: Aged; Amantadine; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenones; Cognition; Cognition Disorders; Creutzfeldt-Jakob Syndrome; Dementia; Humans; Lithium; Movement Disorders; Phenothiazines; Phytotherapy; Plants, Medicinal; Propranolol; Psychotic Disorders; Psychotropic Drugs; Rauwolfia; Thiothixene | 1975 |
The shaking patient. Diagnosis and management of tremor.
Topics: Amantadine; Carbidopa; Cerebellar Diseases; Humans; Levodopa; Parkinson Disease; Propranolol; Tremor | 1977 |
Levodopa-induced myoclonus.
Topics: 5-Hydroxytryptophan; Aged; Amantadine; Amphetamine; Animals; Benztropine; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Guinea Pigs; Humans; Levodopa; Male; Methysergide; Middle Aged; Movement Disorders; Myoclonus; Parkinson Disease; Propranolol; Serotonin; Serotonin Antagonists; Sleep; Trihexyphenidyl | 1975 |
The action of amantadine on the rat uterus: its interaction with oxytocin and the effects of several ionic modifications of the medium.
Topics: Amantadine; Animals; Calcium; Drug Interactions; Female; In Vitro Techniques; Magnesium; Oxytocin; Potassium; Propranolol; Rats; Theophylline; Uterus | 1975 |
Dopaminergic control of growth hormone secretion in normal and acromegalic subjects.
Topics: Acromegaly; Amantadine; Bromocriptine; Ergolines; Growth Hormone; Humans; Hypothalamo-Hypophyseal System; Levodopa; Phentolamine; Pituitary Gland; Propranolol | 1975 |
Interactions of amantadine with the cardiac muscarinic receptor.
Topics: Acetylcholine; Amantadine; Animals; Binding, Competitive; Dihydroalprenolol; Electrocardiography; Guinea Pigs; Heart Atria; Heart Conduction System; Ion Channels; Myocardial Contraction; Nifedipine; Nitrendipine; Propranolol; Quinuclidinyl Benzilate; Receptors, Muscarinic | 1985 |
Treatment of parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease; Phenothiazines; Propranolol | 1972 |
Unusual late neurological sequelae in galactosaemia.
Topics: Adult; Age Factors; Amantadine; Bender-Gestalt Test; Cerebellar Diseases; Diet Therapy; Erythrocytes; Functional Laterality; Galactosemias; Humans; Intellectual Disability; Lactose; Male; Movement Disorders; Muscle Tonus; Nucleotidyltransferases; Propranolol; Speech Disorders | 1973 |
Non-resting tremor in Parkinson's disease.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Humans; Male; Parkinson Disease; Propranolol; Tremor | 1971 |
A possible mechanism of arrhythmia induced by 1-adamantanamine.
Topics: Amantadine; Animals; Arrhythmias, Cardiac; Catecholamines; Cocaine; Electrocardiography; Female; Guinea Pigs; Heart Atria; In Vitro Techniques; Male; Norepinephrine; Propranolol; Rabbits; Reserpine; Ventricular Fibrillation | 1967 |
The pharmacology of olivopontocerebellar atrophy.
Topics: Adult; Amantadine; Atrophy; Baclofen; Brain Diseases; Carbidopa; Cerebellar Ataxia; Female; Humans; Levodopa; Male; Middle Aged; Olivary Nucleus; Pons; Propranolol; Syndrome | 1984 |
Studies on the mechanism of drug-induced lipidosis. Cationic amphiphilic drug inhibition of lysosomal phospholipases A and C.
Topics: Amantadine; Aniline Compounds; Animals; Chlorphentermine; Chlorpromazine; Heptanes; Imipramine; Lipidoses; Liver; Lysosomes; Male; Pharmacology; Phospholipases; Phospholipases A; Propranolol; Rats; Tripelennamine; Type C Phospholipases | 1981 |
Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury.
Topics: Adolescent; Amantadine; Brain Injuries; Dopamine Agents; Dopamine Antagonists; Fever; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Propranolol; Treatment Outcome; Vasodilator Agents | 1999 |
Pharmacologic treatment of cognitive deficits and hypersexuality due to "shaken-baby syndrome".
Topics: Adrenergic beta-Antagonists; Amantadine; Child; Child Behavior Disorders; Cognition Disorders; Dopamine Agents; Female; Humans; Propranolol; Sexual Behavior; Shaken Baby Syndrome; Treatment Outcome | 2000 |